Orthopedic Management of Bisphosphonate Complications: MRONJ & Atypical Femoral Fractures
Key Takeaway
Bisphosphonate therapy can lead to two primary orthopedic complications: Medication-Related Osteonecrosis of the Jaw (MRONJ), characterized by exposed jaw bone, and Atypical Femoral Fractures (AFFs), transverse fractures in the femur. Both involve impaired bone remodeling and specific anatomical vulnerabilities, necessitating careful patient monitoring and multidisciplinary management.
A 72-year-old female presents with 3 months of increasing right thigh pain. She has been on alendronate for 8 years for osteoporosis. You obtain full-length femur radiographs as shown below.
Describe your findings and outline your immediate management plan.
Candidate: The radiograph shows lateral cortical thickening of the proximal femur diaphysis with a transverse lucent line, which is highly suggestive of an incomplete atypical femoral fracture (AFF) secondary to long-term bisphosphonate use. My management would include immediate cessation of the bisphosphonate, non-weight bearing status, and prophylactic intramedullary nailing of the right femur. I would also mandate radiographs of the contralateral femur to rule out bilateral involvement.
Candidates often fail to discuss the "mandatory" contralateral imaging (up to 50% incidence of bilateral involvement). Others suggest "conservative observation" without realizing the high progression risk to complete fracture, or they fail to mention the specific criteria (like >25% cortical involvement) that mandate prophylactic fixation.
The candidate should structure the response: 1. Diagnosis: Confirms incomplete AFF based on the ASBMR criteria (transverse lucency, lateral cortical thickening). 2. Immediate Assessment: Mandatory contralateral imaging to exclude bilateral disease. 3. Surgical Decision: Prophylactic intramedullary nailing is the standard of care given the presence of prodromal pain and cortical thickening. 4. Multidisciplinary Care: Immediate drug holiday and referral to Endocrinology for osteoporosis management optimization (e.g., potential Teriparatide use for bone healing).
How does the pathophysiology of MRONJ (Medication-Related Osteonecrosis of the Jaw) differ from the typical osteomyelitis encountered in orthopedic practice?
Candidate: While both involve bone necrosis, MRONJ is primarily driven by bisphosphonate-induced osteoclast inhibition and anti-angiogenic effects, leading to a failure of bone remodeling and micro-vascular compromise. Unlike typical osteomyelitis, which is a primary infection, MRONJ is primarily a defect in bone metabolism where secondary infection occurs due to exposure to the oral microbiome.
Treating it like routine osteomyelitis with aggressive primary debridement of all necrotic bone. Aggressive surgery in MRONJ often leads to larger wounds that fail to heal because the surrounding bone is biologically "dead" due to suppressed turnover.
The perfect answer emphasizes the "Metabolic-Mechanical-Microbiome" triad. Highlight that MRONJ is "osteonecrosis of metabolic etiology": BP leads to accumulation of microdamage and hypermineralized, brittle bone (metabolic). This exposes the bone to the oral environment (microbiome), resulting in secondary infection. The treatment focus should be "sequestrectomy" and "soft tissue closure" rather than the radical debridement used in hematogenous osteomyelitis.
